Clinical Trials Logo

Filter by:
NCT ID: NCT05097521 Completed - Clinical trials for Chronic Musculoskeletal Pain

Assessing Pain, Patient Reported Outcomes and Complementary and Integrative Health

APPROACH
Start date: March 17, 2021
Phase:
Study type: Observational

The APPROACH Study (Assessing Pain, Patient-Reported Outcomes and Complementary and Integrative Health) assesses the effects of use of practitioner-delivered CIH therapies alone compared to the combination of self-care and practitioner-delivered CIH therapies among Veterans with chronic musculoskeletal pain. The APPROACH study is predominately conducting a secondary analysis of patient-reported data being collected by the Veterans Health Administration's (VA) Office of Patient Centered Care and Cultural Transformation among Veterans using 18 VA medical centers. Those facilities received funding as part of the Comprehensive Addiction and Recovery Act to expand availability of CIH therapies. That patient-reported data is being supplemented with VA electronic health record data and data on the 18 medical centers' business practices (nudges, the instrumental variable). Practitioner-delivered therapies under study include chiropractic care, acupuncture and therapeutic massage, and self-care therapies include Tai Chi/qigong, yoga and meditation. The primary outcomes are improvement in pain severity and pain interference, using the Brief Pain Inventory (BPI), 6 months after initiating CIH therapies compared to baseline. Patients will enter treatment groups based on the CIH therapies they use, as randomizing patients to specific therapies would require withholding therapies routinely offered at VA. The investigators will address selection bias and confounding by using sites' variations in business practices and other encouragements (nudges) to receiving different CIH therapies as a surrogate for direct randomization using instrumental variables econometric methods.

NCT ID: NCT05097352 Completed - Exercise Clinical Trials

Effects of a Short-term Exercise Intervention on Sleep in Women Exposed to Trauma: A Randomized Controlled Trial

Start date: January 24, 2022
Phase: N/A
Study type: Interventional

This study aims to test whether sleep improvements, following 6 weeks of high-intensity interval training exercise among adult women exposed to a traumatic event, are mediated by improvements in heart rate variability or decreased anxiety and hyperarousal symptoms.

NCT ID: NCT05097326 Completed - Clinical trials for Induced Vaginal Delivery

Mifepristone for Labor Induction

MiLI
Start date: June 27, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this trial is to explore mifepristone as an option for induction of labor at term by evaluating the efficacy of mifepristone use for cervical preparation. Since the Labor Induction versus Expectant Management in Low-Risk Nulliparous Women (ARRIVE) trial supporting that elective induction after 39 weeks decreases cesarean sections and morbidity, rates of elective term inductions are increasing. At Lucile Packard Children's Hospital at Stanford University specifically, approximately 40% of spontaneous vaginal deliveries follow induction of labor, with an average induction time of 20 hours. Previous studies have established the maternal and neonatal safety of mifepristone in term inductions, however, this study will assess the difference in overall time from induction to complete cervical dilation, delivery, and the total time on Labor and Delivery.

NCT ID: NCT05097157 Completed - Acne Clinical Trials

Study To Assess A Radiofrequency Microneedling Device For Dermatologic Conditions

Start date: September 3, 2019
Phase: N/A
Study type: Interventional

Subjects are to be enrolled in this clinical study if they are 18 - 55 years old. Up to 120 subjects will be enrolled at multiple study centers. Subjects may receive up to 5 treatments for a wide array of dermatologic conditions in which electrocoagulation and hemostasis is a viable mechanism for means of improvement.

NCT ID: NCT05096780 Completed - Alertness Clinical Trials

Characterizing the Pharmacokinetic Profile of a Novel Encapsulated Caffeine Beverage and Associated Mood and Physiological Effects

Start date: October 8, 2021
Phase: Phase 1
Study type: Interventional

This study is designed to compare self-reported mood states for encapsulated caffeine compared to dose-matched free caffeine, when consumed as a ready-to-drink beverage in healthy subjects. Additionally, this study will characterize the plasma caffeine pharmacokinetic profile for the encapsulated and free caffeine beverages. Two different caffeine levels, 160 and 250 mg will be included, which represent more common caffeine consumption from typical energy drinks. The primary outcomes are alertness ratings from the Caffeine Research visual analog scale (VAS) and PK parameters over 12 hours. Secondary outcomes are Caffeine Research VAS scores (beyond alertness), three other symptom VAS scores, and vital signs for safety.

NCT ID: NCT05096754 Completed - Liver Transplant Clinical Trials

OCS Liver PROTECT Continued Access Protocol (CAP) Continuation Post-Approval Study

Start date: February 3, 2020
Phase:
Study type: Observational

Post-approval observational study of subjects that were enrolled and transplanted in the OCS Liver PROTECT CAP.

NCT ID: NCT05096741 Completed - Liver Transplant Clinical Trials

OCS Liver PROTECT Continuation Post-Approval Study

Start date: January 24, 2016
Phase:
Study type: Observational

Post-approval observational study of subjects that were enrolled and transplanted in the OCS Liver PROTECT Trial.

NCT ID: NCT05096728 Completed - Clinical trials for Preeclampsia With Severe Features

Nifedipine Dosing Daily vs Twice a Day for Pre-eclampsia With Severe Features (NOPPI)

Start date: December 1, 2021
Phase:
Study type: Observational

The investigators propose a randomized controlled unblinded trial to evaluate rates of optimal blood pressure control between Nifedipine 60mg XL once daily vs. Nifedipine 30mg XL twice daily in patients admitted for expectant management with pre-eclampsia with severe features. Patients will be approached for consent when they are placed on 30mg of Nifedipine daily by their primary provider and will be enrolled in the study when the primary provider has made the decision to increase the patient's daily dose of Nifedipine XL from 30mg to 60mg.

NCT ID: NCT05096585 Completed - Obesity Clinical Trials

Sleep Timing on Energy Intake and Energy Expenditure

Start date: August 1, 2021
Phase: N/A
Study type: Interventional

Studies in healthy young adults have shown that abnormal and undesirable physiological changes are a result of chronic sleep curtailment, with implications on inflammatory status, blood glucose regulation, circulating free fatty acids, and insulin sensitivity. Epidemiological studies suggest an increase in energy intake with shortened, sleep and this has been associated with weight gain. Interestingly most studies examining sleep restriction do not consider whether the restricted sleep is due to sleep delay or an advanced wake time. This study will investigate the change in physical activity or food intake during a period of sleep restriction. To date only one study has addressed this question but they only examined one study night and followed their subjects for only 24 hr. The objective of the proposed project is to examine the effects of shortened sleep on potential changes in physical activity and energy intake. The investigators hypothesize that after several nights of short sleep that different strategies are employed to remain awake and these strategies will also vary whether bed time was delayed or wake time was advanced. Aim 1: To examine the effects of sleep timing on energy intake and expenditure during periods of sleep restriction

NCT ID: NCT05096494 Completed - Clinical trials for Moderate to Severe Acute Lower Back Pain

Safety and Efficacy of SP-103 in Subjects With Moderate to Severe Acute Lower Back Pain

Start date: April 29, 2022
Phase: Phase 2
Study type: Interventional

This is a Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety and efficacy of SP-103 in subjects with moderate to severe acute lower back pain.